Literature DB >> 30257212

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.

Joseph Nacson1, John J Krais2, Andrea J Bernhardy2, Emma Clausen2, Wanjuan Feng3, Yifan Wang2, Emmanuelle Nicolas4, Kathy Q Cai5, Rossella Tricarico6, Xiang Hua7, Daniela DiMarcantonio7, Esteban Martinez7, Dali Zong8, Elizabeth A Handorf9, Alfonso Bellacosa6, Joseph R Testa10, Andre Nussenzweig8, Gaorav P Gupta3, Stephen M Sykes7, Neil Johnson11.   

Abstract

BRCA1 functions in homologous recombination (HR) both up- and downstream of DNA end resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is dispensable for the initiation of resection, but whether BRCA1 activity is entirely redundant after end resection is unclear. Here, we found that 53bp1 KO rescued the embryonic viability of a Brca1ΔC/ΔC mouse model that harbors a stop codon in the coiled-coil domain. However, Brca1ΔC/ΔC;53bp1-/- mice were susceptible to tumor formation, lacked Rad51 foci, and were sensitive to PARP inhibitor (PARPi) treatment, indicative of suboptimal HR. Furthermore, BRCA1 mutant cancer cell lines were dependent on truncated BRCA1 proteins that retained the ability to interact with PALB2 for 53BP1 KO induced RAD51 foci and PARPi resistance. Our data suggest that the overall efficiency of 53BP1 loss of function induced HR may be BRCA1 mutation dependent. In the setting of 53BP1 KO, hypomorphic BRCA1 proteins are active downstream of end resection, promoting RAD51 loading and PARPi resistance.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  53BP1; BRCA1; PARP inhibitors; homologous recombination; resistance

Year:  2018        PMID: 30257212      PMCID: PMC6219632          DOI: 10.1016/j.celrep.2018.08.086

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  60 in total

1.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

2.  The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor.

Authors:  C F Chen; S Li; Y Chen; P L Chen; Z D Sharp; W H Lee
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

3.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

4.  BRCA1 pathway function in basal-like breast cancer cells.

Authors:  Sarah J Hill; Allison P Clark; Daniel P Silver; David M Livingston
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

5.  A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.

Authors:  Liu Cao; Xioaling Xu; Samuel F Bunting; Jie Liu; Rui-Hong Wang; Longyue L Cao; J Julie Wu; Tie-Nan Peng; Junjie Chen; Andre Nussenzweig; Chu-Xia Deng; Toren Finkel
Journal:  Mol Cell       Date:  2009-08-28       Impact factor: 17.970

6.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Authors:  J Ross Chapman; Inger Brandsma; Guotai Xu; Jingsong Yuan; Martin Mistrik; Peter Bouwman; Jirina Bartkova; Ewa Gogola; Daniël Warmerdam; Marco Barazas; Janneke E Jaspers; Kenji Watanabe; Mark Pieterse; Ariena Kersbergen; Wendy Sol; Patrick H N Celie; Philip C Schouten; Bram van den Broek; Ahmed Salman; Marja Nieuwland; Iris de Rink; Jorma de Ronde; Kees Jalink; Simon J Boulton; Junjie Chen; Dik C van Gent; Jiri Bartek; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Nature       Date:  2015-03-23       Impact factor: 49.962

7.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Authors:  Rinske Drost; Peter Bouwman; Sven Rottenberg; Ute Boon; Eva Schut; Sjoerd Klarenbeek; Christiaan Klijn; Ingrid van der Heijden; Hanneke van der Gulden; Ellen Wientjens; Mark Pieterse; Aurelie Catteau; Pete Green; Ellen Solomon; Joanna R Morris; Jos Jonkers
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

8.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Authors:  Peter Bouwman; Amal Aly; Jose M Escandell; Mark Pieterse; Jirina Bartkova; Hanneke van der Gulden; Sanne Hiddingh; Maria Thanasoula; Atul Kulkarni; Qifeng Yang; Bruce G Haffty; Johanna Tommiska; Carl Blomqvist; Ronny Drapkin; David J Adams; Heli Nevanlinna; Jiri Bartek; Madalena Tarsounas; Shridar Ganesan; Jos Jonkers
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369

9.  53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms.

Authors:  Raquel Cuella-Martin; Catarina Oliveira; Helen E Lockstone; Suzanne Snellenberg; Natalia Grolmusova; J Ross Chapman
Journal:  Mol Cell       Date:  2016-08-18       Impact factor: 17.970

10.  The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Authors:  Marco Barazas; Stefano Annunziato; Stephen J Pettitt; Inge de Krijger; Hind Ghezraoui; Stefan J Roobol; Catrin Lutz; Jessica Frankum; Fei Fei Song; Rachel Brough; Bastiaan Evers; Ewa Gogola; Jinhyuk Bhin; Marieke van de Ven; Dik C van Gent; Jacqueline J L Jacobs; Ross Chapman; Christopher J Lord; Jos Jonkers; Sven Rottenberg
Journal:  Cell Rep       Date:  2018-05-15       Impact factor: 9.423

View more
  23 in total

Review 1.  Biomarker-Guided Development of DNA Repair Inhibitors.

Authors:  James M Cleary; Andrew J Aguirre; Geoffrey I Shapiro; Alan D D'Andrea
Journal:  Mol Cell       Date:  2020-05-26       Impact factor: 17.970

2.  RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1.

Authors:  Dheva Setiaputra; Cristina Escribano-Díaz; Julia K Reinert; Pooja Sadana; Dali Zong; Elsa Callen; Chérine Sifri; Jan Seebacher; André Nussenzweig; Nicolas H Thomä; Daniel Durocher
Journal:  Mol Cell       Date:  2022-02-24       Impact factor: 17.970

Review 3.  BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.

Authors:  John J Krais; Neil Johnson
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

4.  RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers.

Authors:  John J Krais; Yifan Wang; Andrea J Bernhardy; Emma Clausen; Jessica A Miller; Kathy Q Cai; Clare L Scott; Neil Johnson
Journal:  Cancer Res       Date:  2020-03-25       Impact factor: 12.701

Review 5.  Mechanism, cellular functions and cancer roles of polymerase-theta-mediated DNA end joining.

Authors:  Dale A Ramsden; Juan Carvajal-Garcia; Gaorav P Gupta
Journal:  Nat Rev Mol Cell Biol       Date:  2021-09-14       Impact factor: 94.444

Review 6.  DNA double-strand break repair-pathway choice in somatic mammalian cells.

Authors:  Ralph Scully; Arvind Panday; Rajula Elango; Nicholas A Willis
Journal:  Nat Rev Mol Cell Biol       Date:  2019-07-01       Impact factor: 113.915

7.  Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing.

Authors:  Jessica S Elman; Thomas K Ni; Kristen E Mengwasser; Dexter Jin; Ania Wronski; Stephen J Elledge; Charlotte Kuperwasser
Journal:  Cell Rep       Date:  2019-09-24       Impact factor: 9.423

Review 8.  The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.

Authors:  Madalena Tarsounas; Patrick Sung
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-24       Impact factor: 94.444

9.  BRCA1 Mutational Complementation Induces Synthetic Viability.

Authors:  Joseph Nacson; Daniela Di Marcantonio; Yifan Wang; Andrea J Bernhardy; Emma Clausen; Xiang Hua; Kathy Q Cai; Esteban Martinez; Wanjuan Feng; Elsa Callén; Wei Wu; Gaorav P Gupta; Joseph R Testa; André Nussenzweig; Stephen M Sykes; Neil Johnson
Journal:  Mol Cell       Date:  2020-04-30       Impact factor: 17.970

Review 10.  Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Authors:  Mariana Paes Dias; Sarah C Moser; Shridar Ganesan; Jos Jonkers
Journal:  Nat Rev Clin Oncol       Date:  2021-07-20       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.